iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Aurobindo Pharma's Injectable Facility Receives Seven Observations from US FDA

1 Mar 2024 , 10:31 AM

Aurobindo Pharma received seven observations from the US FDA for its injectable facility in Telangana, as reported on February 29. The US FDA inspected the injectable facility of Eugia SEZ Pvt. Ltd., a 100% step-down subsidiary of Aurobindo Pharma Ltd., from February 19-29. Aurobindo Pharma stated that the observations are procedural and will be addressed within the specified timeframe.

Eugia Pharma Specialities Limited, another subsidiary, has resumed production in terminally sterilized product lines at Unit-III, following a temporary halt to address previous USFDA observations concluded on February 2, 2024. Production in the aseptic lines of the facility is expected to restart in March 2024.

Earlier, the USFDA issued nine observations for Eugia Unit III after inspecting the plant from January 22 to February 2, citing concerns like the lack of procedures to prevent microbiological contamination, incomplete lab records, and inadequate validation of aseptic processes.

Aurobindo Pharma Limited, headquartered in HITEC City, Hyderabad, India, is a multinational pharmaceutical company focusing on generic pharmaceuticals and active pharmaceutical ingredients.

The company operates in six major therapeutic and product areas, including antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterological, and anti-allergics. Aurobindo Pharma markets its products in over 125 countries, with key partners like AstraZeneca and Pfizer.

For feedback and suggestions, write to us at editorial@iifl.com


Related Tags

  • AstraZeneca
  • Aurobindo Pharma
  • news
  • Pfizer
  • Pharma
  • US FDA
sidebar mobile


14 Apr 2024   |   07:25 PM
14 Apr 2024   |   07:23 PM
14 Apr 2024   |   07:21 PM
14 Apr 2024   |   07:15 PM
Read More

Most Read News

12 Apr 2024   |   08:25 PM
12 Apr 2024   |   08:14 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:08 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.


Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp